The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Ki67 immunostaining in primary breast cancer: pathological and clinical associations
Open accessAbstract
Ki67 immunostaining has been performed on 136 primary breast cancers and related to various clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this important characteristic of the tumour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
A prognostic index in primary breast cancer
Haybittle, J. L., Blamey, R. W., Elston, C. W., Johnson, J., Doyle, P. J., Campbell, F. C., Nicholson, R. I., & Griffiths, K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.62 · Cited by 699
Self-citationGerdes, J., Dallenbach, F., Lennert, K., Lemke, H., & Stein, H. (1984) · Hematological Oncology · doi:10.1002/hon.2900020406 · Cited by 313
Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.
Gerdes, J., Lelle, R. J., Pickartz, H., Heidenreich, W., Schwarting, R., Kurtsiefer, L., Stauch, G., & Stein, H. (1986) · Journal of Clinical Pathology · doi:10.1136/jcp.39.9.977 · Cited by 247
Barnard, N. J., Hall, P. A., Lemoine, N. R., & Kadar, N. (1987) · The Journal of Pathology · doi:10.1002/path.1711520407 · Cited by 243
Proliferation-dependent cytotoxicity of anticancer agents: a review.
Valeriote, F. A., & van Putten, L. (1975) · PubMed · Cited by 214
Baisch, H., & Gerdes, J. (1987) · Cell Proliferation · doi:10.1111/j.1365-2184.1987.tb01323.x · Cited by 100
Cited by
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Self-citationde Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Proliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Schlüter, C., Duchrow, M., Wohlenberg, C., Becker, M. H., Key, G., Flad, H. D., & Gerdes, J. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.3.513 · Cited by 765
Monoclonal antibody Ki‐67: its use in histopathology
BROWN, D. C., & GATTER, K. C. (1990) · Histopathology · doi:10.1111/j.1365-2559.1990.tb00788.x · Cited by 639
Metadata
- Authors
- Bouzubar, N., Walker, K., Griffiths, K., Ellis, I., Elston, C., Robertson, J., Blamey, R., & Nicholson, R.
- Venue
- British Journal of Cancer
- Published
- 1989-06
- Volume
- 59
- Issue
- 6
- Pages
- 943-947
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1987622162
- Cited by
- 259
- References
- 7
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ki67 immunostaining in primary breast cancer: pathological and clinical associations. https://app.cochat.ai/papers/10.1038/bjc.1989.200
- The paper
- Bouzubar, N., Walker, K., Griffiths, K., Ellis, I., Elston, C., Robertson, J., Blamey, R., & Nicholson, R. (1989). Ki67 immunostaining in primary breast cancer: pathological and clinical associations. British Journal of Cancer. https://doi.org/10.1038/bjc.1989.200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.